Skip to main content

Table 4 WOMAC pain scores by group and visit

From: A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin

   

Group

   

UP446

250 mg/day

UP446

500 mg/day

Celecoxib

200 mg/day

Placebo

Visit

Baseline

Mean

3.17

3.41

3.20

2.97

  

Std Deviation

0.80

0.93

0.89

0.60

 

30 Days

Mean

2.65

2.44

3.00

2.67

  

Std Deviation

0.77

0.92

0.92

0.62

 

60 Days

Mean

2.63

2.63

2.20

3.29

  

Std Deviation

0.66

0.79

0.66

0.67

 

90 Days

Mean

2.67

2.11

2.27

3.00

  

Std Deviation

0.65

0.86

0.66

0.58